MYLAN-BUPRENORPHINE/NALOXONE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE); NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE)

から入手可能:

MYLAN PHARMACEUTICALS ULC

ATCコード:

N07BC51

INN（国際名）:

BUPRENORPHINE, COMBINATIONS

投薬量:

2MG; 0.5MG

医薬品形態:

TABLET

構図:

BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2MG; NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5MG

投与経路:

SUBLINGUAL

パッケージ内のユニット:

7/100

処方タイプ:

Narcotic (CDSA I)

治療領域:

OPIATE PARTIAL AGONISTS

製品概要:

Active ingredient group (AIG) number: 0252216001; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2019-09-17

製品の特徴

_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MYLAN-BUPRENORPHINE/NALOXONE
Buprenorphine (as Buprenorphine Hydrochloride)
and
Naloxone (as Naloxone Hydrochloride Dihydrate)
Sublingual Tablets 2 mg / 0.5 mg and 8 mg / 2 mg
Partial Opioid Agonist
and
Opioid Antagonist
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision: March 29, 2019
Submission Control No: 225699
_Page 2 of 60 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................
5
ADVERSE REACTIONS
............................................................................................................
17
DRUG INTERACTIONS
............................................................................................................
24
DOSAGE AND ADMINISTRATION
........................................................................................
27
DRUG ABUSE AND DEPENDENCE
.......................................................................................
32
OVERDOSAGE
..........................................................................................................................
33
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
34
STORAGE AND STABILITY
....................................................................................................
38
SPECIAL HANDLING INSTRUCTIONS
.................................................................................
39
DOSAGE FORMS, COMPOSITION AND PACKA